ANDA 200916, held by Pharmobedient. Cytarabine.
As of Nov 16, 2026, ANDA 200916 (Cytarabine), held by Pharmobedient, was first approved by FDA on Dec 13, 2011, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine20MG/ML · injectable;injection | Cytarabine | Discontinued |
| Oct 19, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 13, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 13, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters